Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer

Ovarian Cancer Clinical Trial

Official title:

A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of Fully Human B7H3 CAR-T in Treating Patients With Recurrent Malignant Ovarian Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05211557
• Other study ID #: XYFY2021-KL184-01
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 16, 2021
• Est. completion date: August 31, 2026

Study information

• Verified date: January 2022
• Source: The Affiliated Hospital of Xuzhou Medical University
• Contact: Liantao Li, M.D., Ph.D.
• Phone: +86-516-85582530
• Email: liliantao[@]xzhmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is single center, open-label phase I, non-randomized study which will enroll patients with recurrent advanced ovarian cancer to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T cells (fhB7H3.CAR-Ts) via using a '3+3+3' dose escalation design. In the dose expansion cohort, six patients will be enrolled to further assess their efficacy with the optimal dosage.

Description:

The purpose of this study is to test the safety and efficacy of a newly developed fully human scFv-armed B7H3 targeting chimeric antigen receptor T cells (fhB7H3.CAR-Ts), which are supposed to attack and eliminate B7H3-positive cancer cells. The patients who have been diagnosed as recurrent or relapsed malignant ovarian cancer, especially ovarian cancer patients with refractory ascites, will be potentially enrolled after assessing the expression of B7H3 antigen in tumor tissue by immunohistochemistry staining or ascitic tumor cells by flow cytometry. After enrollment, participants' peripheral blood mononuclear cells will be collected and used to manufacture fhB7H3.CAR-Ts. Before infusion, the patients will receive lymphodepletion chemotherapy with cyclophosphamide and fludarabine for three consecutive days. Two days later after lymphodepletion, the fhB7H3.CAR-Ts would be given through an abdominal catheter for intraperitoneal infusion. From the day of infusion, participants' peripheral blood and ascites will be collected twice a week in the first month for monitoring the survival of fhB7H3.CAR-Ts and evaluating the therapeutic efficacy. Additional follow-up and examination will be performed monthly for the first three month and then trimonthly until one year. Thereafter, annual follow-up will be completed for 5 years. In addition, since the fhB7H3.CAR-Ts containing a RQR8 safety-switch which could be targeted and removed by Rituximab. Participants who experience life-threatening toxicities caused by uncontrollable proliferation of fhB7H3.CAR-Ts will receive infusion of Rituximab (Rituxan or Ruxience or Halpryza) to assess the ability of RQR8 safety-switch to eliminate infused fhB7H3.CAR-Ts. This is an investigator-initiated clinical study to assess first-line clinical performance of novel fhB7H3.CAR-Ts which may help other advanced and recurrent ovarian cancer patients in the future.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: August 31, 2026
• Est. primary completion date: August 31, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Procurement and T-cell production eligibility: a previously evaluation confirmed autologous peripheral blood mononuclear cells can be used for T-cell production

2. Written informed consent and authorization for release of personal health information

3. Subject has adequate performance status as defined by ECOG score of = 2.

4. Expected life expectancy is no less than 12 weeks.

5. Subjects must have histologically or cytologically confirmed ovarian cancer. And cancer tissue or ascitic cancer cells are measured positive for B7H3 expression.

6. Subjects must have recurrent or refractory disease after or during first-line treatment. Defined as: Radiographic progression or Continuous Elevation of CA125.

7. Subjects must have evaluable disease - defined as:

Measurable disease with tumor length = 10mm or enlarged lymph nodes = 15mm according to RECIST v1.1 criteria.

8. Adequate organ function - defined as:

1. Blood routine:

white blood cell count = 3 × 10^9 / L; neutrophil count = 1.5 × 10^9 / L; hemoglobin = 9g/dL; platelet count = 80 × 10^9 / L; INR< 1.5 × ULN; PT, APTT< 1.5 × ULN

2. The liver, kidney, lung and cardiopulmonary function:

Urea and serum creatinine = 1.5 × ULN; Left ventricular ejection fraction = 40%; Baseline oxygen saturation = 95%; Total bilirubin = 1.5 × ULN; ALT and AST = 3 × ULN.

9. Not pregnant with negative serum pregnancy test within 3 days prior to enrollment.

10. Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of highly effective methods of contraception from the time of informed consent until 8 weeks after study treatment discontinuation. -

Exclusion Criteria:

1. Subject has primary immunodeficiency syndrome or history of severe allergic reaction.

2. Subject has active infection with HIV, HTLV, HBV, HCV.

3. Subject has severe, uncontrolled intercurrent bacterial, viral or fungal infection.

4. Subject has a history of gastrointestinal perforation, clinical and/or radiographic evidence of bowel obstruction, or intra-abdominal abscess within 3 months prior to starting treatment.

5. Subject has active malignancy under treatment other than ovarian cancer.

6. Subject has Grade = 3 cardiac dysfunction or symptomatic arrhythmia requiring intervention.

7. Subject is current using of systemic corticosteroids at doses =10 mg prednisone daily or its equivalent.

8. Subject has not recovered from toxicity of previous anti-tumor treatment (CTCAE 5.0).

9. Subject is pregnant or breastfeeding.

10. Unwilling or unable to provide consent/assent for participation in the study. -

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Biological:
• fhB7H3.CAR-Ts
Three dose levels will be evaluated: Dose Level 1 (1×10^6/kg), dose Level 2 (3×10^6/kg) and dose Level 3 (5×10^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10^6/kg /infusion) will be evaluated. Other Name: B7H3 targeting chimeric antigen receptor T cells Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days (Day -5~Day -3) Other Name: FLUDARA Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5) Other Name: Cytoxan

Locations

Country	Name	City	State
China	The Affiliated Hospital of Xuzhou Medical University	Xuzhou	Jiangsu

Sponsors (3)

Lead Sponsor	Collaborator
The Affiliated Hospital of Xuzhou Medical University	IIT MediTech (Jiangsu) Co. Ltd, Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Progress free survival (PFS)	PFS will be assessed from the time of lymphodepletion prior to infusion of fhB7H3.CAR-Ts to	up to 5 years
Other	Overall survival (OS)	OS will be assessed from the date of lymphodepletion prior to infusion of fhB7H3.CAR-Ts to the date of death.	up to 5 years
Primary	Dose limiting toxicity of fully human B7H3 CAR-T cells	Dose limiting toxicity (DLT), including the type, frequency, severity and duration of adverse events, such as cytokine release syndrome (CRS), on-target off-tumor, immune effector cell-associated neurotoxicity syndrome, will be monitored and assessed.	1 month
Primary	Objective response of fully human B7H3 CAR-T cells	Objective response rate (ORR) including complete response (CR), partial response (PR), and/or stable disease, will be determined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.; Complete Response (CR): disappearance of all target lesions. Partial Response (PR): >=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD): no response or less response than Partial or Progressive.; Progressive Disease (PD): 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.	1 month
Secondary	In vivo persistence of fully human B7H3 CAR-T cells	Presence and number of CAR T cells in the peripheral blood and ascites will be assessed.	1 month